AI could make heart monitoring easier for breast cancer patients
NCT ID NCT05623397
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tested an artificial intelligence (AI) model to measure heart rhythm changes (QTc interval) in 70 women with breast cancer starting the drug ribociclib. The goal was to see if the AI could match the accuracy of standard ECG monitoring, potentially allowing simpler devices to be used. The research focused on improving convenience and accessibility of heart safety checks during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CIC - Hôpitaux Universitaires Pitié Salpêtrière, Paris, FRANCE
Paris, PARIS, 75651, France
-
Groupe Ambroise Paré, Hartmann
Neuilly-sur-Seine, 92200, France
-
Hôpital Tenon
Paris, 75020, France
-
Institut Gustave Roussy
Villejuif, 94805, France
Conditions
Explore the condition pages connected to this study.